TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.33
+0.43%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-43.4%
Return on equity
-39.8%
Return on assets
-46.8%
Return on invested capital
0.00x
Asset turnover
-$66.1M
Cash from operations
$0.29
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026